Genetic evidence suggests diabetic neuropathy may be linked to lower Alzheimer's disease risk through tissue-specific gene regulation pathways.
Evidence
A bidirectional two-sample study tested six neuropathic pain subtypes against Alzheimer's disease and added GTEx v10 and GEO GSE156184 transcriptomic annotation, finding diabetic neuropathy associated with reduced AD risk (=0.86, 95% CI: 0.77~0.95, P=0.0043).
Caveat
The inference is limited by population constraints and exploratory molecular annotation, with experimental validation still needed.
Simplified
BACKGROUND: Neuropathic pain (NP) frequently co-occurs with Alzheimer's disease (AD), yet the causal relationship and underlying molecular mechanisms between the two remain unclear, necessitating further investigation to elucidate their intrinsic connection.
METHODS: This study employed a bidirectional two-sample Mendelian randomisation () approach to systematically analyse the association between six NP subtypes and AD. Concurrently, functional annotation and transcriptomic analysis were conducted using the GTEx v10 and GEO GSE156184 databases to explore potential molecular mechanisms.
RESULTS: The study revealed a significant inverse causal effect of diabetic neuropathy (DN) on AD risk (=0.86, 95% CI: 0.77~0.95,=0.0043), with sensitivity analyses confirming the robustness of this finding. Further analysis indicated that DN-associated SNPs regulate four tissue-specific genes includingand. These genes exhibit differential expression in the DN transcriptome and are significantly enriched in key pathways such as mitochondrial function and autophagy. P FAM200A GPC2IVW
CONCLUSION: This study provides the first evidence that DN may exert a protective effect against AD by regulating the aforementioned tissue-specific genes and associated pathways. This finding challenges the conventional understanding that chronic pain exacerbates AD and offers novel potential targets for developing therapeutic strategies. However, due to population limitations in the study, further experimental validation remains necessary.
Key numbers
0.86
Inverse Causal Effect of DN on AD Risk
comparing to Alzheimer's disease risk.
19.2%~40%
Prevalence of
Estimated prevalence among diabetic patients worldwide.
Full Text
We can’t show the full text here under this license.
